TY - JOUR T1 - Validation of a Novel Molecular Assay to the Diagnostic of COVID-19 Based on Real Time PCR with High Resolution Melting JF - medRxiv DO - 10.1101/2021.07.14.21260471 SP - 2021.07.14.21260471 AU - Beatriz Iandra da Silva Ferreira AU - Natália Lins da Silva Gomes AU - Wagner Luis da Costa Nunes Pimentel Coelho AU - Vanessa Duarte da Costa AU - Vanessa Cristine de Souza Carneiro AU - Rafael Lopes Kader AU - Marisa Pimentel Amaro AU - Lívia Melo Villar AU - Fábio Miyajima AU - Soniza Vieira Alves-Leon AU - Vanessa Salete de Paula AU - Luciane Almeida Amado Leon AU - Otacilio Cruz Moreira Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/18/2021.07.14.21260471.abstract N2 - With the emergence of the Covid-19 pandemic, the world faced an unprecedented need for RT-qPCR-based molecular diagnostic tests, leading to a lack of kits and inputs, especially in developing countries. Hence, the costs for commercial kits and inputs were overrated, stimulating the development of alternative methods to detect SARS-CoV-2 in clinical specimens. The availability of the complete SARS-CoV-2 genome at the beginning of the pandemic facilitated the development of specific primers and standardized laboratory protocols for Covid-19 molecular diagnostic. High-sensitive and cost-effective molecular biology technique based on the Melting Temperature differences between purine and pyrimidine bases can be used to the detection and genotyping of pathogens in clinical specimens. Here, a RT-qPCR assays with High Resolution Melting (HRM-RTqPCR) was developed for different regions of the SARS-CoV-2 genome (RdRp, E and N) and an internal control (human RNAse P gene). The assays were validated using synthetic sequences from the viral genome and clinical specimens (nasopharyngeal swabs, serum and saliva) of sixty-five patients with severe or moderate COVID-19 from different states in Brazil, in comparison to a commercial TaqMan RT-qPCR assay, as gold standard. The sensitivity of the HRM-RTqPCR assays targeting N, RdRp and E were 94.12, 98.04 and 92.16%, with 100% specificity to the 3 targets, and diagnostic accuracy of 95.38, 98.46 and 93.85%, respectively. Thus, the HRM-RTqPCR emerges as an alternative and low-cost methodology to increase the molecular diagnostic of patients suspicious for Covid-19, especially in restricted-budget laboratories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been founded by INOVA Fiocruz, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES - Finance Code 001), CNPq and FAPERJ. LMV, SVAL, VSP, OCM are research Fellows from CNPq and FAPERJ (JCNE and CNE). LAAL is a researcher fellow from FAPERJ (JCNE).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committee of Clementino Fraga Filho University Hospital, from Federal University of Rio de Janeiro (UFRJ), CAAE number 31240120.0.0000.5257. All patients or a member of their families signed the consent form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data is available in the manuscrit and supporting tables ER -